Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International reports news on cord blood banking, cord tissue cryopreservation, cellular processing and cryogenic storage. The company operates a private family-use cord blood bank, maintains a public banking program with Duke University, and holds exclusive rights to the PrepaCyte-CB cord blood processing technology.
Recurring updates cover financial results from processing and storage fees, product and public banking revenue, FACT and AABB accreditation matters, FDA-registered and cGMP-/cGTP-compliant operations, and ExtraVault biostorage and distribution services for biopharmaceutical companies and healthcare institutions. Company news also includes dividend actions, credit and capital-allocation decisions, and NYSE American continued-listing compliance developments.
Cryo-Cell International, a leader in private cord blood banking, reported its fiscal 2020 results with revenues of $31.1 million, a slight decline from $31.8 million in fiscal 2019. The company noted net income of $3.6 million, or $0.48 per basic share, an improvement from $2.3 million in 2019. Key revenue components included $29.5 million from processing and storage fees. Despite decreasing costs, the company faced a $1.1 million loss due to the cancellation of a revenue-sharing agreement. Impairment charges on inventory were also noted, amounting to $1.3 million for 2020.
Cryo-Cell International, Inc. (OTC: CCEL) reported its third-quarter financial results for fiscal 2020, revealing consolidated revenues of $8.1 million, slightly down from $8.2 million in Q3 2019. Net income was reported at $784,000, or $0.10 per share, a decline from $1,116,000, or $0.14 per share, in the prior year. Notably, the company incurred a one-time expense of $1,070,900 due to the termination of the Erie Group Revenue Sharing Agreement. Despite challenges, management expressed optimism regarding a licensing agreement with Duke University.